Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial
Year: 2020
Type: article
Abstract: Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD). A previous 26 week open label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI).
DOI: 10.17615/sahy-7789
Authors: Boxer, Adam L, Merrilees, Jennifer, Fields, Scott, Klepac, Kristen, Onyike, Chiadi, Mesulam, M Marsel, Mendez, Mario, Shapira, Jill, Graf-Radford, Neill, Knopman, David S, Wu, Chuang-Kuo, Miller, Bruce L, Lerner, Alan, Kerwin, Diana, Kaufer, Daniel I, Grossman, Murray, Sullivan, Kathryn, Lipowski, Kristine, Neuhaus, John, Kramer, Joel H, Ullah, Jerin, Koestler, Mary
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Larry L. Hillblom Foundation, Alzheimer's Drug Discovery Foundation, Association for Frontotemporal Degeneration, Eli Lilly and Company, Agouron Institute, John Douglas French Alzheimer's Foundation, TauRx Pharmaceuticals, National Institutes of Health, Genentech, University of California, San Francisco, Tau Consortium, National Institute on Aging
OpenAlex ID: W4299786038